Patients and clinicians urge Medicaid and insurers to cover GLP‑1 obesity treatments; insurers warn of high costs

Chair (House Committee on Behavioral Health and Health Care) opened an informational hearing on health insurance coverage of GLP‑1 obesity medications under House Bill 3,517.

Patient advocates and clinicians described obesity as a chronic disease with many related conditions and asked for comprehensive coverage that includes behavioral therapies, FDA‑approved medications and surgical options. Crystal Hartman, a patient advocate from Bend, told the committee she had bariatric surgery and later required GLP‑1 treatment; when she moved to Medicaid in 2024 she lost access to her GLP‑1 and gained 40 pounds despite no change in diet or exercise. "No one with heart disease, diabetes, high blood pressure, or cancer gets told that their disease is too expensive to treat," she said.

Clinicians including Jamie Sweeney (Pacific Obesity Alliance) and Nancy Puzaferri (obesity medicine physician) described the medications’ clinical effects on weight loss and related comorbidities and cited emerging cost‑savings studies. Testimony summarized research showing that meaningful weight loss (for example, 5–20 percent) can be associated with per‑person healthcare savings from reduced diabetes, cardiovascular events and other obesity‑related conditions.

Representatives from insurers raised cost and utilization concerns. Tracy Muday, executive medical director at Regence Blue Cross Blue Shield of Oregon, said newer GLP‑1s and GIP‑GLP‑1 agonists (brand examples: Wegovy, Ozempic, Mounjaro, Zepbound) have shown promise but are expensive (witnesses cited annual prices in the thousands). Muday said ICER analyses and Plan actuarial modeling indicate that broad coverage could add materially to pharmacy spend and premiums; she cited experience in other states where rapidly rising utilization significantly increased plan pharmacy costs.

Witnesses discussed program design options: limiting coverage to higher‑risk cohorts (for example, patients with prior heart attack or stroke), requiring prior authorization, and emphasizing clinician management and wrap‑around services (nutrition counseling, behavioral health) to raise adherence and maximize clinical benefits. Panelists noted that some employer and commercial plans already cover certain GLP‑1s and that a few states' Medicaid programs cover them in varying degrees.

No formal vote was taken. Committee members asked for more actuarial and utilization data and for potential tiered coverage designs that could limit budgetary impacts while prioritizing high‑risk patients.

Ending: The hearing framed GLP‑1 coverage as a trade‑off between clinical benefits for many chronic conditions and potentially large near‑term drug spending. Policymakers requested more detailed cost modeling and options for targeted benefit design before considering a broad coverage mandate.